Interim Report – January to September 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter 2017

Financial Highlights

• Revenue for the 3rd Quarter 2017 amounted to SEK 30.4 (21.5) m, and for the nine month period to 87.7 (76.1) m.
• Operating result for the quarter amounted to SEK -22.5 (-5.2) m, and for the nine month period to -39.9 (-7.5) m.
• Net result for the quarter amounted to SEK -22.4 (-5.2) m, and for the nine month period to -39.7 (-7.5) m.
• Cash flow for the quarter amounted to SEK 22.1 (24.0) m, and for the nine month period to -14.1 (149.2) m.
• Cash and cash equivalents at the end of the period amounted to SEK 112.9 (156.3) m.

Significant Events during the Reporting Period

• In September, we announced that interim data from the ongoing Phase I/II study of ABY-035 was to be presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva.
• In August we filed the clinical trial application (CTA) to progress our psoriasis compound ABY-035 to Phase II.

Significant Events during the rest of the Year

• In May it was announced that we have decided to initiate a Phase II development with ABY-035, our proprietary psoriasis program.
• During the second quarter MedImmune terminated the agreement primarily as a result of changing R&D priorities.
• During the first quarter, the first patient was dosed and evaluated in the clinical trial with ABY-029, to guide cancer surgery.

Significant Events after the Close of the Reporting Period

• In November, the German regulatory agency BfArM approved the clinical trial application (CTA) for our Phase II study with ABY-035.